Kintor Pharmaceutical Limited (9939.HK)
HKD 1.31
(9.17%)
HKD 1.31
(9.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.05 Billion CNY | -10.39% |
| 2022 | -956.44 Million CNY | -115417.41% |
| 2021 | -827.96 Million CNY | 99.79% |
| 2020 | -396.32 Million CNY | -83.15% |
| 2019 | -216.39 Million CNY | -199604.67% |
| 2018 | -108.35 Million CNY | 99.76% |
| 2017 | -44.99 Million CNY | 22.97% |
| 2016 | -58.41 Million CNY | -339.25% |
| 2015 | -13.29 Million CNY | -40.02% |
| 2014 | -9.49 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -846.5 Thousand CNY | -304.42% |
| 2023 Q2 | -209.31 Thousand CNY | 51.14% |
| 2023 FY | - CNY | -10.39% |
| 2022 FY | - CNY | -115417.41% |
| 2022 Q4 | -428.42 Thousand CNY | 18.86% |
| 2022 Q2 | -528.02 Thousand CNY | -6.01% |
| 2021 FY | - CNY | 99.79% |
| 2021 Q2 | -329.87 Thousand CNY | -47.65% |
| 2021 Q4 | -498.08 Thousand CNY | -50.99% |
| 2020 Q4 | -223.42 Thousand CNY | -29.22% |
| 2020 FY | - CNY | -83.15% |
| 2020 Q2 | -172.9 Thousand CNY | -42.3% |
| 2019 Q4 | -121.5 Thousand CNY | -28.06% |
| 2019 Q2 | -94.88 Thousand CNY | 0.0% |
| 2019 FY | - CNY | -199604.67% |
| 2018 FY | - CNY | 99.76% |
| 2017 FY | - CNY | 22.97% |
| 2017 Q4 | -22.92 Thousand CNY | -3.89% |
| 2017 Q2 | -22.06 Thousand CNY | -42.18% |
| 2016 Q4 | -15.52 Thousand CNY | 63.81% |
| 2016 Q2 | -42.89 Thousand CNY | 0.0% |
| 2016 FY | - CNY | -339.25% |
| 2015 FY | - CNY | -40.02% |
| 2014 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 1257.267% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 316.892% |